Chuck Royce's HAE Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 701,242 shares of Haemonetics Corporation (HAE) worth $34.18 M, representing 0.34% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in HAE, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2021, adding 382,812 shares. Largest reduction occurred in Q3 2025, reducing 569,815 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +328,001 | Add 0.00% | 328,000 | $41.35 |
| Q3 2013 | -103,900 | Reduce 31.68% | 224,100 | $39.88 |
| Q4 2013 | -224,100 | Sold Out | 0 | $0.00 |
| Q3 2017 | +249 | New Buy | 249 | $44.18 |
| Q4 2017 | -41 | Reduce 16.47% | 208 | $57.69 |
| Q1 2018 | +19,792 | Add 9515.38% | 20,000 | $73.15 |
| Q2 2018 | -700 | Reduce 3.50% | 19,300 | $89.69 |
| Q3 2018 | -19,300 | Sold Out | 0 | $0.00 |
| Q4 2019 | +30,169 | New Buy | 30,169 | $114.89 |
| Q1 2020 | +346,436 | Add 1148.32% | 376,605 | $99.66 |
| Q2 2020 | +116,588 | Add 30.96% | 493,193 | $89.56 |
| Q3 2020 | +90,415 | Add 18.33% | 583,608 | $87.25 |
| Q4 2020 | +15,148 | Add 2.60% | 598,756 | $118.75 |
| Q1 2021 | -130,171 | Reduce 21.74% | 468,585 | $111.01 |
| Q2 2021 | +132,961 | Add 28.38% | 601,546 | $66.64 |
| Q3 2021 | +382,812 | Add 63.64% | 984,358 | $70.59 |
| Q4 2021 | -276,250 | Reduce 28.06% | 708,108 | $53.04 |
| Q1 2022 | +49,136 | Add 6.94% | 757,244 | $63.22 |
| Q2 2022 | +84,341 | Add 11.14% | 841,585 | $65.18 |
| Q3 2022 | +33,223 | Add 3.95% | 874,808 | $74.03 |
| Q4 2022 | -49,346 | Reduce 5.64% | 825,462 | $78.65 |
| Q1 2023 | +18,292 | Add 2.22% | 843,754 | $82.75 |
| Q2 2023 | +62,538 | Add 7.41% | 906,292 | $85.14 |
| Q3 2023 | +41,258 | Add 4.55% | 947,550 | $89.58 |
| Q4 2023 | +18,805 | Add 1.98% | 966,355 | $85.51 |
| Q1 2024 | +300,259 | Add 31.07% | 1.27 M | $85.35 |
| Q2 2024 | -86,936 | Reduce 6.86% | 1.18 M | $82.73 |
| Q3 2024 | +30,868 | Add 2.62% | 1.21 M | $80.38 |
| Q4 2024 | -57,278 | Reduce 4.73% | 1.15 M | $78.08 |
| Q1 2025 | +8,028 | Add 0.70% | 1.16 M | $63.55 |
| Q2 2025 | +109,761 | Add 9.45% | 1.27 M | $74.61 |
| Q3 2025 | -569,815 | Reduce 44.83% | 701,242 | $48.74 |
Chuck Royce's Haemonetics Corporation Investment FAQs
Chuck Royce first purchased Haemonetics Corporation (HAE) in Q2 2013, acquiring 328,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Haemonetics Corporation (HAE) for 32 quarters since Q2 2013.
Chuck Royce's largest addition to Haemonetics Corporation (HAE) was in Q3 2021, adding 984,358 shares worth $69.49 M.
According to the latest 13F filing for Q3 2025, Chuck Royce's firm, Royce & Associates Lp, owns 701,242 shares of Haemonetics Corporation (HAE), valued at approximately $34.18 M.
As of the Q3 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.34% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Haemonetics Corporation (HAE) was 1,271,057 shares, as reported at the end of Q2 2025.